Objectives: 1) To obtain preference scores from patients with breast cancer in Singapore for different stages of breast cancer and hormonal therapy-related adverse effects, and 2) to determine the association of patients' demographic and clinical characteristics with those preference scores. Methods: A total of 22 health states were used to elicit preference values from 64 patients with breast cancer. At each interview, 14 health states were randomly selected and rated by the patient using the visual analogue scale and standard gamble methods to derive health state preference scores, which were recalibrated to the scale of 0 (death) and 1 (perfect health). Results: Mean adjusted visual analogue scale scores ranged from 0.25 (no recurrence with ischemic cerebrovascular events) to 0.82 (no recurrence with no adverse effects). Mean adjusted standard gamble scores ranged from 0.31 (distant recurrence with chemotherapy-related adverse effects) to 0.80 (no recurrence with no adverse effects). Adverse effects ischemic cerebrovascular events and spine fracture resulted in the greatest decline in health state preference scores. Age, ethnicity, education level, and prior chemotherapy were associated with preference scores. Having children was not found to be associated with the preference scores. Conclusions: Taking into account disease progression and hormonal therapy-related adverse effects as well as their impact on healthrelated quality of life, this study quantifies patients' preference for various breast cancer-related health states. The findings offer valuable information for future cost-utility analysis of breast cancer treatments.
Introduction
Breast cancer is one of the leading causes of morbidity and mortality among women in the world. Its substantial lifetime treatment expenditure ranges from US $20,000 to US $100,000 per patient, with hospitalization and outpatient therapies largely contributing to the magnitude of those expenditures [1] [2] [3] [4] . In Singapore, breast cancer is the most common cancer with the highest mortality rate in the female population [5] . Moreover, it is estimated that there are 1430 new breast cancer cases every year, and this number increases at 3% annually [6, 7] . Each woman in Singapore has approximately a 6.1% chance of developing breast cancer in her lifetime, and the age-adjusted incidence among Singaporean women is one of the highest in Asia [6, 7] .
In addition to local treatments such as surgery and radiotherapy, systemic treatments for breast cancer such as hormonal, chemo-targeted, and molecular-targeted drug regimens are significant in their roles as standard treatment [8] . Over the years, the effectiveness of hormonal therapies such as tamoxifen and aromatase inhibitors has been well established for the management of estrogen-receptor-positive breast cancer [9] [10] [11] [12] . Furthermore, adjuvant hormonal therapy has been progressively essential in breast cancer treatment because of the increasing incidence of early stage breast malignancy and the rising number of breast cancer survivors. In addition to providing a significant reduction in disease recurrence and death, however, various hormonal therapies are associated with adverse effects on patients' quality of life [13, 14] . The presence of adverse effects can lead to discontinuation of therapy and it may be more important to patients than clinicians have yet understood [15] . Indeed, successful treatment is greatly affected by patients' management and tolerance of adverse effects. Although the impact of cancer therapies on survival may be indistinct, their effect on patients' quality of life is expected to be decidedly negative. To understand patients' preference for different treatment outcomes, utility values can be used to quantify the impact on patients' health-related quality of life (HRQOL).
In previous utility assessment studies, the number of breast cancer-related health states and treatment adverse effects evaluated has been limited [16] [17] [18] [19] , and no study has been conducted in an Asian population. This study aimed to elicit preferences for different stages of breast cancer and adverse effects related to hormonal therapies in patients in Singapore, and also aimed to identify associations of patients' demographic and clinical characteristics with those preference scores. Such preference data will be useful for future cost-utility analyses and could improve clinical decisions regarding breast cancer therapies.
Methods

Health States
A total of 22 health states (death, perfect health, worst health, and current health, along with 18 hypothetical health states relating to different stages of breast cancer and adverse effects of hormonal therapies) were developed in a previous study through literature review and validation by an oncology expert panel [20] . The health state descriptions illustrated common hormonal treatment-associated adverse effects (cataract, hip fracture, wrist fracture, spine fracture, vaginal bleeding, hot flushes, musculoskeletal disorder, pulmonary embolism, endometrial cancer, deep vein thrombosis, and ischemic cardiovascular events) and breast cancer-related disease stages (no recurrence, locoregional recurrence, distant recurrence, and new contralateral breast cancer). These health states were used in the present study.
Preference Assessment
Study design and subjects
This cross-sectional study was approved by the National Health Group Domain Specific Review Boards and was conducted in the Cancer Centre of National University Cancer Institute, Singapore, from November 2011 to January 2012.
Patients could be recruited for this study if they were female, diagnosed with breast cancer, able to communicate in English or Mandarin, at least 21 years old, and able to function without apparent cognitive impairment. Patients with breast cancer were identified by the hospital pharmacy system on the basis of hormonal and chemotherapy agents prescribed specifically for breast cancer treatment. Potential respondents were invited to participate in the study during their consultation or chemotherapy appointments. All respondents who completed the interview were reimbursed with Singapore $30 for their participation.
Study interviews
The face-to-face study interviews were conducted by two trained interviewers in either Mandarin or English, depending on patient preference. An interview script was preplanned and carefully followed to reduce interviewer bias or inconsistency. The respondents were asked to provide sociodemographic information as well as their breast cancer treatment history, including their experiences with symptoms or diseases after breast cancer diagnosis. Patients also rated their current health status on a fivepoint poor-to-excellent scale.
Each health state description was displayed on a laminated card. The descriptions for different health domains of the health states were presented in different colored text to help patients understand and contrast the various health states. Because 22 health states were considered to be too many for accurate evaluation as well as too much of a burden for respondents, a core random sample approach was applied to select 14 health states for each interviewee [21] . Each patient assessed the same core set of 4 health states (death, perfect health, worst health, and current health) and an additional set of 10 other health states that were selected by a random number generator. All health states were presented in a random sequence to reduce potential biases due to presentation order or respondent fatigue.
Preferences can be measured by both direct and indirect methods. The indirect method, or the use of generic HRQOL instruments, was not selected because Singapore-specific population-based values for generic HRQOL instruments, such as the EuroQol five-dimension (EQ-5D) questionnaire, are not available. Instead, two direct valuation methods, the visual analogue scale (VAS) and standard gamble (SG) methods, were used in this study. For elicitation of health state preferences using VAS, a rating scale was displayed as a line with distinct intervals from 0 to 100. Respondents were asked to read and understand all 14 cards with health state descriptions and then rank the various health states on the scale in descending order according to their preference. The most preferred state and the least preferred state, which might or might not be death, were anchored at the 100 and 0 marks, respectively. Respondents were then asked to give each of the remaining health states a value between 0 and 100, with the intervals between adjacent health states reflecting the differences in preference as deemed by the patients [22] [23] [24] [25] .
In the SG assessment, a color schematic diagram illustrating a probability wheel on a computer screen was used as a visual support to facilitate comprehension of the process. Respondents were offered three options: 1) to live in a particular health state under evaluation with certainty for the rest of her life; 2) to have p probability of living in perfect health for the rest of her life with a (1 À p) probability of immediate death; and 3) to indicate that the previous two options were equal. The probability p was varied at an increment of 5% until the respondent switched to a different option or chose the third option. If any health state was rated to be worse than death in the VAS assessment, the respondents were also asked to choose between immediate death and a gamble of perfect health and that particular health state [22] [23] [24] [25] .
Statistical Analysis
Preference scores obtained for each health state were presented by means, medians, and SDs. Raw preference scores obtained from both VAS and SG techniques were calibrated to the scale of 0 (death) and 1 (perfect health) [22] . For VAS assessment, if death was indicated as the least preferred health state, the preference score for the other health states would take the scale value of its placement. In cases in which death was not indicated as the least preferred health state, the formula (x À d)/(100 À d), where d and x denote the scale value of death and the particular health state, respectively, was used for the calculation of the adjusted preference score. In the SG method, if a health state was perceived to be worse than death, the formula for calibration was as follows: adjusted preference score ¼ Àp/(1 À p), where p is the probability, or raw preference score, of that particular health state. If the health state was perceived to be more desirable than death, the preference score for the health state was equal to the probability p [22] .
Because of the small sample size, nonparametric tests were used in the data analysis. The Wilcoxon signed rank test was used to examine the difference in preferences among the health states and the difference between VAS-and SG-derived preference scores. Spearman's correlation coefficient, the MannWhitney U test, and the Kruskal-Wallis test were performed where appropriate to determine the association between patient characteristics (i.e., age, ethnicity, language version, education level, having children, experience with chemotherapy, and experience with hormonal therapy) and preference scores. In addition, the Mann-Whitney U test was used to examine the association between experience of the common adverse effects of hormonal therapy (i.e., hot flushes and musculoskeletal disorder) and the preference scores of the corresponding health states. All
statistical analyses were conducted using SPSS for Windows, version 17.
Results
Participant Characteristics
A total of 94 eligible patients with breast cancer were approached, with a response rate of 68.1% (n ¼ 64). A summary of the respondents' characteristics is presented in Table 1 . Their mean age was 50.1 Ϯ 8.2 years. Most of the respondents were Chinese (79.7%), married (76.6%), and had children (75.0%). Nearly half had completed secondary education (48.4%) and had a gross household monthly income between Singapore $1000 and Singapore $2999 (42.2%). A large proportion of the respondents had undergone prior surgery (79.7%) and chemotherapy (81.3%) for breast cancer treatment. The most common adverse effects or diseases experienced by the respondents during their breast cancer treatment were hot flushes (25.0%) and musculoskeletal disorder (10.9%). No respondent had wrist fracture, deep vein thrombosis, pulmonary embolism, ischemic cerebrovascular events, or endometrial cancer.
Summary of preference scores
The mean, SD, and median of the VAS-and SG-derived preference scores for the health states assessed are presented in Table 2 . After recalibration, the mean adjusted VAS scores ranged from 0.25 (no recurrence with ischemic cerebrovascular events) to 0.82 (no recurrence with no adverse effects). The mean adjusted SG scores ranged from 0.31 (distant recurrence with adverse effects from chemotherapy) to 0.80 (no recurrence with no adverse effects).
The mean adjusted VAS and SG scores for "current health" were 0.79 and 0.76, respectively. Among all hypothetical health states assessed, "no recurrence with any adverse effects" had the highest mean adjusted VAS and SG scores, whereas "no recurrence with hot flushes" and "no recurrence with vaginal bleeding" had the next highest preference scores. After excluding "worst health" and "death," "no recurrence with ischemic cerebrovascular events" had the lowest mean VAS score, while "distant recurrence with chemotherapy-related adverse effects" had the lowest SG score. Among the adverse effects of hormonal therapy that may take place in the "no recurrence" state, ischemic cerebrovascular events and spine fracture resulted in the largest decline in preference scores.
Comparison among health states and between VAS-and SGderived preference scores
The preference scores of health states with no recurrence of breast cancer were generally higher than those of health states with recurrence. In addition, the preference scores of distant recurrence health states were consistently lower than those of locoregional recurrence health states. These trends were observed in both VAS-and SG-derived preference scores. The study results also showed that a few health states had preference scores significantly different from one another. Specifically, "no recurrence with no adverse effects" was consistently rated higher than all the other health states (P o 0.001) except "current health" whereas "worst health" and "death" were rated significantly lower than all the other health states (P o 0.001). The health states with mild adverse effects, such as hot flushes and vaginal bleeding, had higher preference scores than did recurrence health states (P o 0.05). The preference scores of health states describing severe or life-threatening adverse effects such as cataract, hip fracture, spine fracture, endometrial cancer, and pulmonary embolism, however, were not consistently different from those of the recurrence health states (P 4 0.05).
The mean SG scores were higher than the corresponding VAS scores for most of the health states. The Wicoxon signed rank test results, however, showed that the differences were not significant except for "no recurrence with hip fracture" (P ¼ 0.047) and "locoregional recurrence with general adverse effects" (P ¼ 0.03).
Association between patient characteristics and preference scores
The study results showed that age, ethnicity, language version, and education level had a significant association with the preference scores of certain health states. Specifically, the Kruskal-Wallis test and post hoc multiple comparison found that Chinese patients had lower VAS scores for "distant recurrence with chemotherapy adverse effects" than did Malay patients. Moreover, patients with higher education levels had higher SG scores than did those with lower education levels for adverse effects 2 0 1 4 ) In the analysis of the association between experience and preference scores, patients who had had chemotherapy were found to have higher mean adjusted VAS and SG scores for "worst health" than did those who had not. In addition, experience of hormonal therapy and its common adverse effects of hot flushes and musculoskeletal disorder were not associated with the preference scores of the corresponding health states.
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Discussion
This study reports the preference scores of patients with breast cancer in Singapore for different disease stages and adverse effects related to hormonal therapies. Patients with breast cancer were chosen as the study population because healthy individuals may not have sufficient knowledge specific to breast cancer treatment to evaluate the relevant health states [26] . Nevertheless, it is notable that the patient population usually reports higher utility values than does the general public population [27, 28] . This difference may be explained by various hypotheses such as response shift where alterations in health status or experience of a disease lead to a change in internal standards for health state evaluation. In addition, patient adaptation to the disease and public failure to predict such adaptation can be another contributing factor for the difference [29] .
As indicated by our study results, the health states with locoregional and distant recurrence obtained lower preference scores than did the "no recurrence" health states because the disease progression is often accompanied with increased pain and distress. In addition, unsurprisingly, distant recurrence health states were given lower preference scores because patients with distant recurrence are required to undergo harsh cancer treatments that often lead to worse adverse effects. Adverse effects such as ischemic cerebrovascular events and spine fracture were found to have the lowest preference scores, which may be explained by the life-threatening nature of ischemic cerebrovascular events and the risk of immobility and neurological complications related to spine fracture. These adverse effects undoubtedly lead to a marked decline in patients' HRQOL. 
Similar to other studies, the SG-derived preference scores were found to be higher than the VAS-derived scores for most health states, which could be due to risk aversion [24, 25] . In the SG assessment, patients were required to make their decision under uncertainty where risk-averse individuals were less likely to take the risk of "immediate death" in the gamble option. Therefore, the preference scores would be higher as those patients were more inclined to choose the option of staying in the health state with certainty and avoiding the risk of immediate death unless the gamble option offered a very favorable probability of survival.
The preference study of oncology nurses in Singapore that assessed the same set of health states [20] yielded results similar to those of the present study in that both reported that ischemic cerebrovascular events and spine fracture were the adverse effects with the lowest preference scores among the "no recurrence" health states whereas vaginal bleeding and hot flushes had the least negative effects on patients' HRQOL. Unlike the previous study, however, the VAS-derived mean preference score of "worst health" was positive in our study, which may reveal that the patients were more accepting than the nurses of worst health and perhaps more adaptable to changes in lifestyle and mindset than outsiders may have predicted.
The association between education levels and preference scores was observed in a few adverse effects in the present study. Other studies with similar findings proposed that education may act as a shield to the detrimental aspects of breast cancer treatment by facilitating a better understanding of ways to manage associated complications [30, 31] . Our study results also showed that chemotherapy experience led to an increase in the preference score of worst health, which indicates that these patients were more willing to accept that health state than were patients without such experience. Evidence has suggested that medical knowledge or experience with a disease or condition may affect subjects' valuation of health states [32] . The favorable experience with the chemotherapy outcomes and cognitive adaptation may explain the effect of chemotherapy experience on preference scores.
Our study used VAS and SG for preference measurement. These two methods have been shown to be practical, reliable, and valid for use in numerous populations, including those in Singapore settings [33, 34] . Preference studies using these methods have reported high completion rates, and VAS has the additional benefit of a lower cost [33] . These descriptions accord with our study's high completion rate, indicating that respondents in general did not encounter problems during preference assessment. Moreover, the framing effect was minimized with the use of perfect health and immediate death health states as the two anchor points in our study. As such, the health state descriptions and assessment procedures herein may be applied to future preference studies in the general public or other patient populations to generate preference scores for comparison. In addition, the preference data reported in this study can be useful for cost-utility analyses of breast cancer treatments, particularly hormonal therapies. With the consistent entry of new and costly options for breast cancer treatment, such economic evaluations will be essential in the allocation of limited health care resources and the improvement of clinical decision making for optimal cancer care.
One of the limitations of our study is the small sample size. Moreover, to reduce respondent burden, patients were asked to assess only 14 of the 22 health states under evaluation. Although there is no minimum sample size requirement for preference assessment, a larger sample would have been more desirable for the investigation of the associations between patient characteristics and preference scores. Furthermore, the inclusion of only outpatients may have led to a selection bias toward those with better health and mobility, as no patients with breast cancer from inpatient settings or terminal care facilities were recruited. These patients were excluded because they were likely to have difficulty understanding and completing the interview. To reduce the time and cognitive burden of the respondents, the ping-pong approach was not used in the SG assessment. It is acknowledged that using the 50% perfect health as the starting point may have resulted in narrower ranges of preference scores and that using the pingpong approach could have minimized the starting point bias.
Conclusions
Taking into account disease progression and hormonal therapyrelated adverse effects as well as their impact on HRQOL, this study quantifies patients' preference for various breast cancerrelated health states. The findings offer valuable information for future cost-utility analysis of breast cancer treatments, which can aid clinical decision making regarding cancer therapies. In addition, this study may be used as a basis for future research to obtain utility data from other Asian populations.
